Intrapartum magnesium sulfate and need for intensive delivery room resuscitation

Dany E Weisz,1 Sandesh Shivananda,2 Elizabeth Asztalos,1,3 Wendy Yee,4 Anne Synnes,5 Shoo K Lee,3 Prakesh S Shah,3,6 on behalf of the Canadian Neonatal Network

ABSTRACT
Objective To evaluate the association of intrapartum magnesium sulfate for fetal neuroprotection (MgSO4-FN) with the delivery room resuscitation and neonatal outcomes of preterm infants in an era of minimisation of invasive mechanical ventilation.

Design Retrospective cohort study.

Setting Neonatal intensive care units in the Canadian Neonatal Network.

Patients and intervention Preterm infants (230 to 31 weeks gestational age) born in 2011 or 2012. Resuscitation requirements and neonatal outcomes were compared between infants exposed and unexposed to intrapartum MgSO4-FN.

Main outcome measures The primary outcome was a composite outcome of ‘intensive resuscitation’, defined as the need for intubation and ventilation or chest compressions or epinephrine administration in the delivery room. Secondary outcomes included mortality and major neonatal morbidities.

Results Of 6015 eligible infants, 1387 (23.1%) were exposed to intrapartum MgSO4-FN. Significantly fewer MgSO4-FN infants (41.0% vs 44.6%, p=0.02) required intensive resuscitation. However, after adjustment for confounders, this difference was no longer significant (adjusted OR (AOR) 0.88; 95% CI 0.66 to 1.17). Infants exposed to MgSO4-FN had increased odds of death (AOR 0.61; 95% CI 0.40 to 0.94), but there was no difference in neonatal morbidities compared with the unexposed infants.

Conclusions Intrapartum MgSO4 for fetal neuroprotection was not associated with an increased need for intensive delivery room resuscitation in this cohort of preterm infants.

INTRODUCTION
In 2010 and 2011, the Royal College of Obstetricians and Gynaecologists, American College of Obstetricians and Gynaecologists, and Society of Obstetricians and Gynaecologists of Canada (SOGC) published guidelines recommending the administration of intrapartum magnesium sulfate (MgSO4) to pregnant women at imminent risk of early preterm birth for fetal neuroprotection.1–3 These recommendations were based on five randomised placebo-controlled trials (RCT) and three meta-analyses that reported a reduction in the risk of cerebral palsy or gross motor dysfunction in survivors.4–11

The effect of intrapartum MgSO4 on the neonatal outcomes has been a source of concern, based on the risk of hypotonia, hypotension and respiratory depression associated with its administration.12–17 Previous studies have reported that MgSO4-exposed infants did not have increased need for delivery room resuscitation7–9 and no correlation has been identified between cord blood magnesium concentrations and the need for intensive resuscitation.18 However, these trials were conducted in an era (1995–2005) of routine endotracheal intubation and surfactant administration for extremely preterm infants.19

Intubation and mechanical ventilation for preterm infants has evolved into a selective practice for those who have inadequate respiratory effort or demonstrate respiratory insufficiency after treatment with nasal continuous positive airway pressure.20–23 Thus, intrapartum MgSO4 administration may have different implications under current resuscitation practices where strategies are used to avoid invasive mechanical ventilation. While a single-centre cohort study reported no difference in the need for delivery room resuscitation in MgSO4-exposed versus unexposed preterm infants,24 contemporary population-level evaluations of the effect of MgSO4 exposure on the need for respiratory support have not been reported.

The objective of this study was to evaluate the association of intrapartum MgSO4 for fetal neuroprotection with the delivery room resuscitation and neonatal outcomes of preterm infants. We hypothesised that exposure to intrapartum MgSO4 would
be associated with an increased need for intensive resuscitation, defined as intubation and ventilation, or chest compressions or epinephrine administration, in the delivery room.

**METHODS AND STUDY POPULATION**

The Canadian Neonatal Network (CNN) maintains a national database for the purpose of outcomes evaluation, benchmarking and quality improvement. Data from all eligible neonatal intensive care unit (NICU) admissions are collected and submitted by trained research assistants who abstract relevant data from the charts at each participating centre after institutional approval (either from a local Research Ethics Board or an institutional quality improvement committee). Details of CNN data collection and data management have been previously published.23

Data from all eligible infants born 23rd to 31st weeks gestational age (GA) admitted to CNN NICUs between 1 January 2011 and 31 December 2012, were used for this study.

**Study design and outcomes**

This study was a retrospective cohort study. Infants whose mothers received intrapartum MgSO4 for fetal neuroprotection prior to delivery were considered exposed to MgSO4. Infants with major congenital anomalies and those who were moribund on admission (ie, a physician, in consultation with the parents, had made an explicit decision not to provide life support at the time of birth) were excluded from the analysis. It was decided, a priori, to exclude infants whose MgSO4 exposure status was missing. The primary outcome was a composite outcome of ‘intensive resuscitation’, defined as the need for intubation and ventilation, or chest compressions or epinephrine administration, in the delivery room. Secondary outcomes included neonatal mortality, severe neonatal morbidities (retinopathy of prematurity (ROP) ≥ stage 3, necrotising enterocolitis (NEC) ≥ stage 2, bronchopulmonary dysplasia (BPD), grade 3 or 4 intraventricular hemorrhage or periventricular leukomalacia, late-onset sepsis) and a composite outcome defined as neonatal mortality or severe neonatal morbidity. A subgroup analysis was planned to evaluate the outcomes in infants ≤ 28 weeks and >28 weeks GA, given the previously demonstrated benefit of MgSO4 in the lower GA group7 and the perceived increased risk of adverse effects of MgSO4 in this group.

Fetal neuroprotection may have been the actual indication for intrapartum MgSO4 in infants whose indication was recorded as ‘unknown’, and so we performed sensitivity analyses imputing these infants as having been exposed to MgSO4 for fetal neuroprotection. We also examined the characteristics of infants exposed to intrapartum MgSO4 for pre-eclampsia and tocolysis, and performed sensitivity analyses comparing the outcomes of all infants exposed to MgSO4 (for any indication) versus unexposed infants.

**Variable definitions**

Study variables were defined according to the CNN manual.26

GA was defined as the best estimate based on the date of in vitro fertilisation, early ultrasound, obstetric history and examination or by paediatric estimate, in that order. For infants exposed to intrapartum MgSO4, the indication for administration was recorded as one of: fetal neuroprotection, other (tocolysis or pre-eclampsia/eclampsia), or unknown, based on the information available in the infant’s chart.26 Data on immediate resuscitation details within the first 30 min after birth were recorded for all infants with respect to minimal support to extensive resuscitation. For outborn infants (defined as infants delivered in Level 1 or Level 2 centres), resuscitation details were extracted from neonatal transport services documentation. All units followed the Canadian modification of the Neonatal Resuscitation Program.27 Neonatal outcome definitions were standardised. Intraventricular haemorrhage was defined according to the criteria of Papile et al28 from the worst findings on head ultrasound during the infant’s stay in the NICU. Periventricular echogenicity or leukomalacia was detected based on ultrasound or MRI findings. ROP was classified according to the international classification.29 NEC was defined according to Bell’s criteria (stage 2 or higher).30 BPD was defined as the need for any form of respiratory support (oxygen or positive pressure support) at 36 weeks corrected GA or at the time of discharge to level 2 NICUs.31 Late-onset sepsis was defined as the presence of a pathogenic organism in either a blood or cerebrospinal fluid culture in a symptomatic infant after the third day of life.

**Statistical analysis**

Descriptive statistical methods were applied to describe the study population. Infant characteristics and outcomes were compared between MgSO4 and No-MgSO4 groups using the χ2 test for categorical variables and the t test or Wilcoxon–Rank Sum test for continuous variables. To further determine the effect of MgSO4, we estimated ORs of receiving intensive resuscitation and of the neonatal outcomes using multiple logistic regression models with a generalised estimating equation approach to account for the correlated data within each NICU site (or site effect). This approach uses weighted combinations of observations to extract the appropriate amount of information from correlated data.32 The covariates included in the full model were GA, gender, small for gestational age (SGA), outborn status, chorioamnionitis, mode of delivery, antenatal steroid use and multiple gestation. Data management and statistical analyses were performed using SAS V9.2 (SAS Institute, Cary, North Carolina, USA).

**RESULTS**

There were 6759 infants with a GA between 23rd and 31st weeks admitted to all 30 NICUs in the CNN during the study period. Of these infants, we excluded 350 (5.2%) who were moribund or had major congenital anomalies, and 394 (6.4%) infants with missing MgSO4 information (figure 1). The remaining 6015 infants were included in the analysis. Of these, 2147 (35.7%) infants were exposed to intrapartum MgSO4 and 3868 (64.3%) were unexposed. Of the exposed infants, MgSO4 was administered for fetal neuroprotection in 1387 infants (magnesium sulfate—fetal neuroprotection group (MgSO4-FN)), for pre-eclampsia or tocolysis in 214 infants (MgSO4—other indication group), and the indication for administration was unknown in 546 infants (magnesium sulfate—indication unknown group (MgSO4-UI)).

Baseline characteristics revealed the MgSO4-FN infants had lower GA, lower birth weight and were more likely to have received antenatal corticosteroids (ACS), be SGA and inborn compared with unexposed infants (table 1). There was no significant difference in the proportion of infants with 5 min Apgar score <7 or SNAP-II score ≥ 20 (table 2). Significantly fewer MgSO4-FN infants (41.0% vs 44.6%, p = 0.02) required intensive resuscitation (intubation and ventilation or chest compressions or epinephrine) (table 3).

After adjustment for confounders, the MgSO4-FN infants had lower odds of death compared with the unexposed infants, but there was no significant difference in the odds of intensive resuscitation, severe neonatal morbidities or the composite outcome (table 3). In the subgroup analyses, MgSO4-exposed infants of...
23–28 weeks GA had increased BPD but reduced mortality of borderline significance, and there were no other statistically significant differences in neonatal outcomes in either subgroup (tables 4 and 5). Subgroup interaction testing revealed that these GA subgroup differences were not statistically significant.

Compared with the MgSO₄-FN group, the MgSO₄-other indication and MgSO₄-IU infants were slightly more mature (28.0±2.3 vs 28.5±2.0 and 28.4±2.1 weeks GA, respectively, both p<0.01), had less chorioamnionitis (23.3% vs 4.1% and 14.5%, respectively, both p<0.01), and were more likely to be premature.

### Table 1 Patient characteristics

<table>
<thead>
<tr>
<th></th>
<th>MgSO₄ for fetal neuroprotection (n=1387)</th>
<th>No MgSO₄ (n=3868)</th>
<th>Difference (95% CI)</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational age, weeks (SD)</td>
<td>28.0 (2.3)</td>
<td>28.3 (2.3)</td>
<td>−0.3 (−0.5 to −0.2)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Birth weight, g (SD)</td>
<td>1160 (374)</td>
<td>1232 (402)</td>
<td>−72 (−95 to −48)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Birth weight &lt;1000 g, n (%)</td>
<td>526 (37.9)</td>
<td>1207 (31.2)</td>
<td>6.7 (3.8 to 9.2)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Birth weight &lt;1500 g, n (%)</td>
<td>1113 (80.2)</td>
<td>2845 (73.6)</td>
<td>6.6 (4.1 to 9.2)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>GA group, n (%)</td>
<td></td>
<td></td>
<td></td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>22–28 weeks</td>
<td>731 (52.7)</td>
<td>1813 (46.9)</td>
<td>5.8 (2.8 to 8.9)</td>
<td></td>
</tr>
<tr>
<td>29–31 weeks</td>
<td>656 (47.3)</td>
<td>2055 (53.1)</td>
<td>−5.8 (−8.9 to −2.8)</td>
<td></td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>623 (44.9)</td>
<td>1709 (44.2)</td>
<td>0.7 (−3.8 to 2.3)</td>
<td>0.64</td>
</tr>
<tr>
<td>SGA (BW &lt;10%), n (%)</td>
<td>147 (10.6)</td>
<td>273 (7.1)</td>
<td>3.5 (1.7 to 5.4)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Outborn, n (%)</td>
<td>81 (5.8)</td>
<td>714 (18.5)</td>
<td>−12.7 (−14.0 to −11.0)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Chorioamnionitis, n (%)</td>
<td>265 (23.3)</td>
<td>569 (20.8)</td>
<td>2.4 (−0.5 to 5.3)</td>
<td>0.09</td>
</tr>
<tr>
<td>Caesarean, n (%)</td>
<td>766 (55.3)</td>
<td>2196 (56.9)</td>
<td>−1.6 (−4.7 to 1.4)</td>
<td>0.29</td>
</tr>
<tr>
<td>Antenatal corticosteroids, n (%)</td>
<td>1342 (97.1)</td>
<td>3170 (83.4)</td>
<td>13.7 (12.3 to 15.2)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Maternal hypertension, n (%)</td>
<td>257 (18.8)</td>
<td>405 (10.6)</td>
<td>8.2 (5.9 to 10.5)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>Multiple gestation, n (%)</td>
<td>429 (30.9)</td>
<td>1166 (30.1)</td>
<td>0.8 (−2.0 to 3.6)</td>
<td>0.58</td>
</tr>
<tr>
<td>ROM</td>
<td></td>
<td></td>
<td></td>
<td>0.13</td>
</tr>
<tr>
<td>&lt;24 h</td>
<td>1063 (78.2)</td>
<td>2860 (76.7)</td>
<td>1.5 (−1.1 to 4.1)</td>
<td></td>
</tr>
<tr>
<td>24 h–1 week</td>
<td>175 (12.9)</td>
<td>463 (12.4)</td>
<td>0.5 (−1.6 to 2.5)</td>
<td></td>
</tr>
<tr>
<td>&gt;1 weeks</td>
<td>121 (8.9)</td>
<td>404 (10.8)</td>
<td>−1.9 (−3.8 to 0.1)</td>
<td></td>
</tr>
<tr>
<td>Infants GA established in first trimester, n (%)</td>
<td>835 (60.2)</td>
<td>1896 (49.0)</td>
<td>11.2 (8.2 to 14.2)</td>
<td>&lt;0.01</td>
</tr>
</tbody>
</table>

*p*2 test for categorical variables and t test or Wilcoxon Rank test, as appropriate, for continuous variables, were used for the comparisons.

1By in vitro fertilisation, early ultrasound or last menstrual period.

BW, birth weight; GA, gestational age; MgSO₄, magnesium sulfate; ROM, rupture of membranes; SGA, small for gestational age.

---

Figure 1 Study algorithm. CNN, Canadian Neonatal Network; NICUs, neonatal intensive care units; GA, gestational age; MgSO₄, magnesium sulfate.
MgSO4-IU and MgSO4-FN groups were combined (n=1933) and compared vs all MgSO4-exposed infants (fetal neuroprotection, F62 Weisz DE, comparing the neonatal outcomes of MgSO4-unexposed infants (placebo) infants7 and a subsequent secondary analysis identified no correlation between cord blood magnesium concentrations (placebo) infants and a subsequent secondary analysis identified no correlation between cord blood magnesium concentrations and the need for intensive resuscitation.18 A Cochrane review reported no difference between treatment groups in the proportion of infants with a 5 min Apgar score <7.9 In this study, infants exposed to MgSO4 for fetal neuroprotection had a lower adjusted odds of death compared with the unexposed infants. Although the meta-analyses demonstrated a reduction in the risk of the combined outcome of cerebral palsy

### Table 2 Resuscitation outcomes

<table>
<thead>
<tr>
<th>MgSO4 for fetal neuroprotection (n=1387)</th>
<th>No MgSO4 (n=3868)</th>
<th>Difference (95% CI)</th>
<th>p Value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any resuscitation needed†, n (%)</td>
<td>1324 (95.7)</td>
<td>3624 (93.7)</td>
<td>2.0 (0.7 to 3.3)</td>
</tr>
<tr>
<td>CPAP only, n (%)</td>
<td>561 (40.7)</td>
<td>1165 (30.5)</td>
<td>10.2 (7.2 to 13.1)</td>
</tr>
<tr>
<td>Bag-mask or Neopuff ventilation, n (%)</td>
<td>781 (56.6)</td>
<td>2344 (61.4)</td>
<td>–4.8 (–7.8 to –1.7)</td>
</tr>
<tr>
<td>Intubation and ventilation, n (%)</td>
<td>557 (40.4)</td>
<td>1669 (43.7)</td>
<td>–3.3 (–6.4 to –0.3)</td>
</tr>
<tr>
<td>Chest compressions, n (%)</td>
<td>54 (3.9)</td>
<td>266 (6.9)</td>
<td>–3.0 (–4.4 to –1.7)</td>
</tr>
<tr>
<td>Epinephrine (ETT or IV), n (%)</td>
<td>26 (1.9)</td>
<td>119 (3.1)</td>
<td>–1.2 (–2.1 to –0.3)</td>
</tr>
<tr>
<td>Maximum FiO2, median (IQR)</td>
<td>60 (40–100)</td>
<td>80 (40–100)</td>
<td>–20 (–30 to –10)</td>
</tr>
<tr>
<td>5 min Apgar &lt;7, n (%)</td>
<td>412 (29.8)</td>
<td>1205 (31.6)</td>
<td>–1.8 (–4.7 to 1.0)</td>
</tr>
<tr>
<td>Surfactant use, n (%)</td>
<td>735 (53.0)</td>
<td>2163 (55.9)</td>
<td>–2.9 (–6.0 to 0.1)</td>
</tr>
<tr>
<td>SNAP-II score &gt;20, n (%)</td>
<td>1086 (79.3)</td>
<td>3074 (80.6)</td>
<td>–1.3 (–3.8 to 1.2)</td>
</tr>
</tbody>
</table>

*χ² test for categorical variables and Wilcoxon Rank Sum test for continuous variables.
† Any resuscitation defined as mask continuous positive airway pressure or positive pressure ventilation, endotracheal tube intubation and ventilation, chest compressions or epinephrine.
CPAP, continuous positive airway pressure; ETT, endotracheal tube; FiO2, fraction of inspired oxygen; IV, intravenous; MgSO4, magnesium sulfate; SNAP-II, score for neonatal acute physiology II.

### Table 3 Univariate and multivariate analyses of outcomes for all infants

<table>
<thead>
<tr>
<th>MgSO4 for fetal neuroprotection (n=1387)</th>
<th>No MgSO4 (n=3868)</th>
<th>p Value</th>
<th>Unadjusted OR (95% CI)*</th>
<th>Adjusted OR (95% CI)**</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intensive resuscitation†, n (%)</td>
<td>566 (41.0)</td>
<td>1702 (44.6)</td>
<td>0.02</td>
<td>0.87 (0.76 to 0.98)</td>
</tr>
<tr>
<td>Death, n (%)</td>
<td>98 (7.1)</td>
<td>367 (9.5)</td>
<td>&lt;0.01</td>
<td>0.73 (0.58 to 0.92)</td>
</tr>
<tr>
<td>Bronchopulmonary dysplasia, n (%)</td>
<td>276 (21.4)</td>
<td>703 (20.0)</td>
<td>0.28</td>
<td>1.09 (0.93 to 1.18)</td>
</tr>
<tr>
<td>NEC stage ≥2, n (%)</td>
<td>83 (6.0)</td>
<td>197 (5.1)</td>
<td>0.20</td>
<td>1.19 (0.91 to 1.55)</td>
</tr>
<tr>
<td>Grade 3 or 4 IVH or PVL, n (%)</td>
<td>176 (13.8)</td>
<td>493 (14.3)</td>
<td>0.62</td>
<td>0.95 (0.79 to 1.15)</td>
</tr>
<tr>
<td>ROP stage ≥3, n (%)</td>
<td>67 (8.9)</td>
<td>158 (8.9)</td>
<td>0.95</td>
<td>1.01 (0.74 to 1.36)</td>
</tr>
<tr>
<td>Sepsis, n (%)</td>
<td>226 (16.3)</td>
<td>587 (15.2)</td>
<td>0.32</td>
<td>1.09 (0.92 to 1.29)</td>
</tr>
<tr>
<td>Composite outcome§, n (%)</td>
<td>495 (35.7)</td>
<td>1378 (35.6)</td>
<td>0.97</td>
<td>1.00 (0.88 to 1.14)</td>
</tr>
</tbody>
</table>

*Unadjusted and adjusted OR determined for MgSO4 versus No-MgSO4.
† Adjusted for GA, sex, small for GA, outcome status, chorioamnionitis, mode of delivery, antenatal corticosteroid use and multiple gestation using multiple logistic regression models with GEE approach to account for the correlated data within each site (or site effects).
‡Intensive resuscitation defined as need for intubation and ventilation or chest compressions or epinephrine administration in the delivery room.
§Composite outcome defined as mortality or any major neonatal morbidity.
GA, gestational age; IVH, intraventricular haemorrhage; MgSO4, magnesium sulfate; NEC, necrotising enterocolitis; PVL, periventricular leukomalacia; ROP, retinopathy of prematurity; GEE, generalised estimating equation.
or death, no reduction was seen in the risk of death alone. Differences between this study population and the populations evaluated in the neuroprotection trials may account for this discrepancy in the odds of death. The pregnant women enrolled in the largest neuroprotection trial were randomised, on average, 1 week prior to delivery, with the potential for monitoring and optimisation of maternal-infant status prior to delivery. In this cohort study, some mothers may not have had the latency period between clinical presentation and delivery for optimisation of maternal-infant status prior to delivery. Given that this may be associated with an indication with GEE approach to account for the correlated data within each site (or site effects).

### Table 4

Univariate and multivariate analyses of outcomes for infants 23–28 weeks gestational age

<table>
<thead>
<tr>
<th></th>
<th>MgSO4 for fetal neuroprotection (n=731)</th>
<th>No MgSO4 (n=1813)</th>
<th>p Value</th>
<th>Unadjusted OR (95% CI)*</th>
<th>Adjusted OR (95% CI)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intensive resuscitation†, n (%)</td>
<td>451 (62.4)</td>
<td>1210 (67.8)</td>
<td>&lt;0.01</td>
<td>0.79 (0.66 to 0.94)</td>
<td>0.89 (0.67 to 1.18)</td>
</tr>
<tr>
<td>Death, n (%)</td>
<td>92 (12.6)</td>
<td>325 (17.9)</td>
<td>&lt;0.01</td>
<td>0.65 (0.51 to 0.85)</td>
<td>0.65 (0.43 to 1.00)</td>
</tr>
<tr>
<td>Bronchopulmonary dysplasia, n(%)</td>
<td>246 (38.3)</td>
<td>566 (37.6)</td>
<td>0.75</td>
<td>1.03 (0.85 to 1.25)</td>
<td>1.30 (1.03 to 1.65)</td>
</tr>
<tr>
<td>NEC stage ≥2, n (%)</td>
<td>63 (8.7)</td>
<td>138 (7.6)</td>
<td>0.38</td>
<td>1.15 (0.84 to 1.57)</td>
<td>1.05 (0.78 to 1.42)</td>
</tr>
<tr>
<td>Grade 3 or 4 IVH or PVL, n (%)</td>
<td>150 (21.3)</td>
<td>380 (22.0)</td>
<td>0.69</td>
<td>0.96 (0.77 to 1.19)</td>
<td>1.11 (0.77 to 1.60)</td>
</tr>
<tr>
<td>ROP stage ≥3, n (%)</td>
<td>64 (12.4)</td>
<td>153 (12.9)</td>
<td>0.79</td>
<td>0.96 (0.70 to 1.31)</td>
<td>0.86 (0.59 to 1.25)</td>
</tr>
<tr>
<td>Sepsis, n (%)</td>
<td>176 (24.1)</td>
<td>447 (24.7)</td>
<td>0.76</td>
<td>0.97 (0.79 to 1.18)</td>
<td>0.91 (0.75 to 1.11)</td>
</tr>
<tr>
<td>Composite outcome‡, n (%)</td>
<td>418 (57.2)</td>
<td>1075 (59.3)</td>
<td>0.33</td>
<td>0.92 (0.77 to 1.09)</td>
<td>1.24 (0.97 to 1.61)</td>
</tr>
</tbody>
</table>

*Unadjusted and adjusted OR determined for MgSO4 versus No-MgSO4.
†Adjusted for GA, sex, small for GA, outborn status, chorioamnionitis, mode of delivery, antenatal corticosteroid use and multiple gestation using multiple logistic regression models with GEE approach to account for the correlated data within each site (or site effects).
‡First, we excluded infants who were moribund at birth (designated to receive comfort care) or exposed to MgSO4 for other indications, as MgSO4 for fetal neuroprotection may have been withheld in these scenarios. Second, we adjusted for outborn status and ACS in the analyses. These factors likely represent, or are surrogates for, common reasons for non-administration of MgSO4. Finally, medical contraindications to MgSO4 (eg, magnesium hypersensitivity, renal impairment, heart block, myocardial damage and neuromuscular disorders) comprise the other reasons for non-administration, but are uncommon.

Additionally, the resuscitation requirements of the MgSO4-unexposed infants in this study are similar to that of other reported cohorts, suggesting that they were not appreciably more ill so as to comparatively make the MgSO4-FN group appear healthier. The 43.7% rate of delivery room intubation and ventilation in the MgSO4-unexposed group in this

### Table 5

Univariate and multivariate analyses of outcomes for infants 29–31 gestational age

<table>
<thead>
<tr>
<th></th>
<th>MgSO4 for fetal neuroprotection (n=656)</th>
<th>No MgSO4 (n=2055)</th>
<th>p Value</th>
<th>Unadjusted OR (95% CI)*</th>
<th>Adjusted OR (95% CI)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intensive resuscitation‡, n (%)</td>
<td>115 (17.5)</td>
<td>492 (24.2)</td>
<td>&lt;0.01</td>
<td>0.67 (0.53 to 0.83)</td>
<td>0.82 (0.57 to 1.19)</td>
</tr>
<tr>
<td>Death, n (%)</td>
<td>6 (0.91)</td>
<td>42 (2.1)</td>
<td>0.06</td>
<td>0.44 (0.18 to 1.05)</td>
<td>0.74 (0.36 to 1.51)</td>
</tr>
<tr>
<td>Bronchopulmonary dysplasia, n(%)</td>
<td>30 (4.6)</td>
<td>137 (6.8)</td>
<td>0.05</td>
<td>0.67 (0.44 to 0.99)</td>
<td>0.73 (0.49 to 1.07)</td>
</tr>
<tr>
<td>NEC stage ≥2, n (%)</td>
<td>20 (3.0)</td>
<td>59 (2.9)</td>
<td>0.81</td>
<td>1.06 (0.63 to 1.78)</td>
<td>1.03 (0.57 to 1.85)</td>
</tr>
<tr>
<td>Grade 3 or 4 IVH or PVL, n (%)</td>
<td>26 (4.5)</td>
<td>113 (6.6)</td>
<td>0.07</td>
<td>0.67 (0.43 to 1.04)</td>
<td>0.66 (0.40 to 1.06)</td>
</tr>
<tr>
<td>ROP stage ≥3, n (%)</td>
<td>3 (1.3)</td>
<td>5 (0.8)</td>
<td>0.56</td>
<td>1.53 (0.36 to 6.46) NA</td>
<td></td>
</tr>
<tr>
<td>Sepsis, n (%)</td>
<td>50 (7.6)</td>
<td>140 (6.8)</td>
<td>0.48</td>
<td>1.23 (0.81 to 1.58)</td>
<td>1.23 (0.91 to 1.67)</td>
</tr>
<tr>
<td>Composite outcome‡, n (%)</td>
<td>77 (11.7)</td>
<td>303 (14.7)</td>
<td>0.05</td>
<td>0.77 (0.59 to 1.01)</td>
<td>0.77 (0.59 to 1.01)</td>
</tr>
</tbody>
</table>

*Unadjusted and adjusted OR determined for MgSO4 versus No-MgSO4.
†Adjusted for GA, sex, small for GA, outborn status, chorioamnionitis, mode of delivery, antenatal corticosteroid use and multiple gestation using multiple logistic regression models with GEE approach to account for the correlated data within each site (or site effects).
‡Unable to estimate due to few affected infants.
§Composite outcome defined as mortality or any major neonatal morbidity.
GA, gestational age; IVH, intraventricular haemorrhage; MgSO4, magnesium sulfate; NEC, necrotising enterocolitis; PVL, periventricular leukomalacia; ROP, retinopathy of prematurity; GEE, generalised estimating equation.
study is similar to the rate of intubation and ventilation for all infants <31 weeks GA in the 2011 and 2012 CNN censuses (43.7% and 44.9%, respectively). Our rate is comparable with the Vermont Oxford Network rates of 47.8% and 46.9% for 2011 and 2012, respectively, among very low birth weight infants.

The strengths of this study include the use of a large population-level database with meticulous collection of outcomes, covariates measured in a standardised manner, a pragmatic setting and a large sample size of preterm neonates of 23–31 weeks GA at birth. Importantly, this study included complete data on a large number of important antenatal confounders, permitting adjustment for these factors.

This study is limited by a lack of available database information during the study period to identify the indication for MgSO4 administration for a minority of infants. Five-hundred and forty-six infants were exposed to intrapartum MgSO4, but the indication was unknown at the time of data abstraction. The increased incidence of maternal hypertension in the MgSO4-IU group suggests that pre-eclampsia/eclampsia may have been the indication for MgSO4 in some of these cases. It is, nonetheless, reassuring that the MgSO4-FN and MgSO4-IU groups had similar resuscitation requirements and that when the MgSO4-FN group was considered alone, or in combination with the MgSO4-IU infants, the exposed infants did not have increased need for intensive resuscitation or adverse neonatal outcomes compared with unexposed infants.

The beneficial effects of intrapartum MgSO4 may occur within a therapeutic window, below which there may not be a measureable effect, within which there is probable benefit and above which there may be no additional value but potential for fetal toxicity. Higher doses of MgSO4 and increased infant serum magnesium concentrations have been associated with higher mortality and a variable trend toward increased need for delivery room resuscitation. The SOGC recommends the use of a 4 g intravenous loading dose followed by a 1 g/h maintenance infusion (maximum duration 24 h, or total dose of 28 g) to pregnant women at risk of preterm delivery at <32 weeks GA, ideally within 4 h before birth. In our study, data were not available regarding the dose or timing of MgSO4 administration or infant serum magnesium concentrations at the time of birth. Infants whose mother did not receive the recommended dose or whose most recent MgSO4 infusion concluded more than 4 h prior to birth, were included in the MgSO4 group. While we were unable to evaluate the relationship between MgSO4 dose, timing or serum magnesium concentration at birth and outcomes, this study provides a pragmatic evaluation of the population-level adverse effects and outcomes associated with intrapartum MgSO4 administration. Additional studies are needed to determine the optimal dose and timing of MgSO4 for fetal neuroprotection.

Our study captures subjects during a period of uptake of new knowledge, which is reflected in the low MgSO4 exposure rate in this study. The first Cochrane review recommending the use of MgSO4 for neuroprotection was published in February 2009, followed by publication of the Canadian guidelines in May 2011. A knowledge translation intervention is currently in progress. Surveillance studies should monitor the rate of MgSO4 exposure and may further clarify the factors that affect its administration.

CONCLUSION

The population-level administration of MgSO4 for fetal neuroprotection is not associated with an increased need for intensive delivery room resuscitation or adverse neonatal outcomes under contemporary resuscitation practices. While this supports the short-term safety of intrapartum MgSO4 administration in preterm infants, additional studies are needed to evaluate the population-level effectiveness of MgSO4 in reducing the targeted outcome of neuromotor impairment.

Acknowledgements We would like to thank Mr Xiang Ye for statistical support and Dr Ruth Warre for editorial help, both from the Mother Infant Research Center, Mount Sinai Hospital, Toronto, during preparation of this manuscript.

Collaborators Site Investigators of the Canadian Neonatal Network: Prakash S Shah (Director, Canadian Neonatal Network and Site Investigator, Mount Sinai Hospital, Toronto, Ontario); Wayne Andrews (Janeway Children’s Health and Rehabilitation Centre, St John’s, NL); Keith Barrington (Sainte Justine Hospital, Montreal, QC); Wendy Yee (Foothills Medical Centre, Calgary, Alberta); Barbara Bullied (Everett Chalmers Hospital, Fredericton, New Brunswick, Canada); Rody Canning (Monton Hospital, Moncton, NB); Ruben Alvaro (St. Boniface General Hospital, Winnipeg, Manitoba); Kimberly Dow (Kingston General Hospital, Kingston, Ontario); Michael Dunn (Sunnybrook Health Sciences Centre, Toronto, Ontario); Adele Harrison (Victoria General Hospital, Victoria, British Columbia, Canada); Andrew James (Hospital for Sick Children, Toronto, Ontario); Zarin Kalapesi (Regina General Hospital, Regina, Saskatchewan, Canada); Lajos Kovacs (Jewish General Hospital, Montreal, QC); Orlando da Silva (St. Joseph’s Health Centre, London, Ontario); Douglas D. McMillan (IWK Health Centre, Halifax, Nova Scotia, Canada); Cecil Ojah (St. John Regional Hospital, St. John, New Brunswick, Canada); Abraham Pelovsiki/Khalid Aziz (Royal Alexandra Hospital, Edmonton, Alberta, Canada); Bruno Pierboeuf (Centre hospitalier universitaire de Quebec, Sainte Foy, QC); Patricia Riley (Montreal Children’s Hospital, Montreal, QC); Daniel Faucher (Royal Victoria Hospital, Montreal, QC); Nicole Rouvinez-Bouali (Children’s Hospital of Eastern Ontario, Ottawa, Ontario); Koravangattu Sankaran (Royal University Hospital, Saskatoon, Saskatchewan, Canada); Mary Seshia (Health Sciences Centre, Winnipeg, Manitoba); Sandesh Shivananda (Hamilton Health Sciences Centre, Hamilton, Ontario); Zenon Cieslak (Royal Columbian Hospital, New Westminster, British Columbia, Canada); Anne Synnes (Children’s and Women’s Health Centre of British Columbia, Vancouver, British Columbia, Canada); Herve Walti (Centre Hospitalier Universitaire de Sherbrooke, Fleurimont, QC), Shoo K. Lee (Chairman, Canadian Neonatal Network).

Contributors DEW: conceptualised and designed the study, reviewed the protocol, assembled the cohort, interpreted the data, drafted the initial manuscript, reviewed and revised the manuscript, and approved the final manuscript. SS and EA: conceptualised and designed the study, reviewed and revised the manuscript, and approved the final manuscript. WY: analysed and interpreted the data, reviewed and revised the manuscript and approved the final manuscript. AS: conceptualised the study, reviewed and revised the manuscript and approved the final manuscript. SKL: analysed and interpreted the data, reviewed and revised the manuscript, and approved the final manuscript. PSS: conceptualised and designed the study, reviewed the protocol, interpreted the data, reviewed and revised the manuscript, and approved the final manuscript.

Funding This study was supported by a Team Grant to the Maternal-Infant Care Team from the Canadian Institute of Health Research’s Health Services and Policy Research from the Canadian Institute of Health Research. This study was supported by a Team Grant to the Maternal-Infant Care Team from the Canadian Institute of Health Research’s Health Services and Policy Research from the Canadian Institute of Health Research. This study was supported by a Team Grant to the Maternal-Infant Care Team from the Canadian Institute of Health Research’s Health Services and Policy Research from the Canadian Institute of Health Research. This study was supported by a Team Grant to the Maternal-Infant Care Team from the Canadian Institute of Health Research’s Health Services and Policy Research from the Canadian Institute of Health Research.

Competing interests PSS is supported by an Aplied Chair in Maternal and Child Health Services and Policy Research from the Canadian Institute of Health Research.

Ethics approval Research Ethics Board at each participating institution in the Canadian Neonatal Network.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES


**Supplementary Table 1:** Patient characteristics, including infants exposed to magnesium sulphate for other indications (pre-eclampsia or tocolysis) and infants exposed to magnesium sulphate with indication unknown.

<table>
<thead>
<tr>
<th></th>
<th>MgSO₄ for fetal neuroprotection (n = 1,387)</th>
<th>No MgSO₄ (n = 3,868)</th>
<th>MgSO₄ for other indications¹ (n=214)</th>
<th>MgSO₄ with indication unknown (n = 546)</th>
<th>p-value² (FN vs. No-MgSO₄)</th>
<th>p-value² (FN vs. Other Indication)</th>
<th>p-value² (FN vs. IU)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestational Age, weeks, mean (SD)</td>
<td>28.0 (2.3)</td>
<td>28.3 (2.3)</td>
<td>28.5(2.0)</td>
<td>28.4 (2.1)</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Birth weight, g, mean (SD)</td>
<td>1,160 (374)</td>
<td>1,232 (402)</td>
<td>1,057 (326)</td>
<td>1180 (389)</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
<td>0.32</td>
</tr>
<tr>
<td>Birth weight &lt;1000g, n(%)</td>
<td>526 (37.9)</td>
<td>1,207 (31.2)</td>
<td>100 (46.9)</td>
<td>192 (35.2)</td>
<td>&lt; 0.01</td>
<td>0.01</td>
<td>0.26</td>
</tr>
<tr>
<td>Birth weight &lt; 1500g, n (%)</td>
<td>1,113 (80.2)</td>
<td>2,845 (73.6)</td>
<td>189 (88.7)</td>
<td>424 (77.7)</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
<td>0.20</td>
</tr>
<tr>
<td>GA group, n(%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>&lt; 0.01</td>
<td>0.06</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>22 - 28 weeks</td>
<td>731(52.7)</td>
<td>1,813 (46.9)</td>
<td>98 (45.8)</td>
<td>252 (46.1)</td>
<td>&lt; 0.01</td>
<td>0.06</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>29 - 31 weeks</td>
<td>656 (47.3)</td>
<td>2,055 (53.1)</td>
<td>116 (54.2)</td>
<td>294 (53.8)</td>
<td>&lt; 0.01</td>
<td>0.01</td>
<td>0.04</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>623 (44.9)</td>
<td>1,709 (44.2)</td>
<td>97 (45.5)</td>
<td>273 (50.1)</td>
<td>0.64</td>
<td>0.01</td>
<td>0.04</td>
</tr>
<tr>
<td>SGA (BW &lt; 10%), n(%)</td>
<td>147 (10.6)</td>
<td>273 (7.1)</td>
<td>56 (26.3)</td>
<td>80 (14.7)</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
<td>0.01</td>
</tr>
<tr>
<td>Outborn, n(%)</td>
<td>81 (5.8)</td>
<td>714 (18.5)</td>
<td>13 (6.1)</td>
<td>39 (7.1)</td>
<td>&lt; 0.01</td>
<td>0.01</td>
<td>0.16</td>
</tr>
<tr>
<td>Chorioamnionitis, n(%)</td>
<td>265 (23.3)</td>
<td>569 (20.8)</td>
<td>6 (4.1)</td>
<td>55 (14.5)</td>
<td>0.09</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Caesarean, n(%)</td>
<td>766 (55.3)</td>
<td>2,196 (56.9)</td>
<td>183 (85.5)</td>
<td>361 (66.2)</td>
<td>0.29</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Antenatal corticosteroids, n(%)</td>
<td>1,342 (97.1)</td>
<td>3,170 (83.4)</td>
<td>203 (95.3)</td>
<td>516 (95.0)</td>
<td>&lt; 0.01</td>
<td>0.16</td>
<td>0.03</td>
</tr>
<tr>
<td>Maternal hypertension, n(%)</td>
<td>257 (18.7)</td>
<td>405 (10.6)</td>
<td>174 (81.3)</td>
<td>226 (42.2)</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Multiple gestation, n(%)</td>
<td>429 (30.9)</td>
<td>1,166 (30.1)</td>
<td>27 (12.7)</td>
<td>153 (28.0)</td>
<td>0.58</td>
<td>&lt; 0.01</td>
<td>0.21</td>
</tr>
<tr>
<td>ROM</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.13</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>&lt;24 hrs</td>
<td>1,063 (78.2)</td>
<td>2,860 (76.7)</td>
<td>200 (94.8)</td>
<td>446 (84.5)</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>24 hrs - 1 week</td>
<td>175 (12.9)</td>
<td>463 (12.4)</td>
<td>10 (4.7)</td>
<td>59 (11.2)</td>
<td>&lt; 0.01</td>
<td>0.07</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>&gt; 1 weeks</td>
<td>121 (8.9)</td>
<td>404 (10.8)</td>
<td>1 (0.5)</td>
<td>23 (4.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infants GA established in first trimester¹, n(%)</td>
<td>835 (60.2)</td>
<td>1,896 (49.0)</td>
<td>108 (50.5)</td>
<td>284 (52.0)</td>
<td>&lt; 0.01</td>
<td>0.07</td>
<td>&lt; 0.01</td>
</tr>
</tbody>
</table>

¹ 'Other' indications refers to pre-eclampsia or tocolysis.
2. Chi-square test for categorical variables and T test or Wilcoxon Rank test, as appropriate, for continuous variables were used for the comparisons.

3. By IVF or LMP or Early US

BW, birthweight; FN, fetal neuroprotection; GA, gestational age; MgSO₄, magnesium sulphate; ROM, rupture of membranes; SD, standard deviation; SGA, small for gestational age; IU, indication unknown
**Supplementary Table 2:** Resuscitation outcomes, including infants exposed to magnesium sulphate for other indications (pre-eclampsia or tocolysis) and infants exposed to magnesium sulphate with indication unknown.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>MgSO₄ for fetal neuroprotection (n = 1,387)</th>
<th>No MgSO₄ (n = 3,868)</th>
<th>MgSO₄ for other indications¹ (n = 214)</th>
<th>MgSO₄ with indication unknown (n = 546)</th>
<th>p-value² (FN vs. No-MgSO₄)</th>
<th>p-value² (FN vs. Other Indication)</th>
<th>p-value² (FN vs. IU)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any resuscitation needed³, n(%)</td>
<td>1,324 (95.7)</td>
<td>3,624 (93.8)</td>
<td>204 (95.8)</td>
<td>521 (95.4)</td>
<td>&lt; 0.01</td>
<td>0.97</td>
<td>0.76</td>
</tr>
<tr>
<td>CPAP only, n(%)</td>
<td>561 (40.7)</td>
<td>1,165 (30.5)</td>
<td>65 (30.7)</td>
<td>178 (32.6)</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
</tr>
<tr>
<td>Bag/mask or Neopuff ventilation, n(%)</td>
<td>781 (56.6)</td>
<td>2,344 (61.4)</td>
<td>136 (64.1)</td>
<td>319 (58.4)</td>
<td>&lt; 0.01</td>
<td>0.04</td>
<td>0.35</td>
</tr>
<tr>
<td>Intubation and ventilation, n(%)</td>
<td>557 (40.4)</td>
<td>1,669 (43.7)</td>
<td>63 (29.7)</td>
<td>204 (37.4)</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
<td>0.28</td>
</tr>
<tr>
<td>Chest compressions, n(%)</td>
<td>54 (3.9)</td>
<td>266 (7.0)</td>
<td>9 (4.2)</td>
<td>24 (4.4)</td>
<td>&lt; 0.01</td>
<td>0.82</td>
<td>0.60</td>
</tr>
<tr>
<td>Epinephrine (ETT or IV), n(%)</td>
<td>26 (1.9)</td>
<td>119 (3.1)</td>
<td>4 (1.9)</td>
<td>8 (1.5)</td>
<td>0.01</td>
<td>0.99</td>
<td>0.54</td>
</tr>
<tr>
<td>Maximum FiO₂, median (IQR)</td>
<td>60 (40 - 100)</td>
<td>80 (40 - 100)</td>
<td>65 (40 - 100)</td>
<td>70 (40 - 100)</td>
<td>&lt; 0.01</td>
<td>0.17</td>
<td>0.02</td>
</tr>
<tr>
<td>5 minute Apgar &lt; 7, n(%)</td>
<td>412 (29.8)</td>
<td>1,205 (31.6)</td>
<td>74 (34.7)</td>
<td>143 (26.2)</td>
<td>0.09</td>
<td>0.14</td>
<td>0.12</td>
</tr>
<tr>
<td>Surfactant use, n(%)</td>
<td>735 (53.0)</td>
<td>2,163 (55.9)</td>
<td>121 (56.5)</td>
<td>298 (54.6)</td>
<td>0.02</td>
<td>0.33</td>
<td>0.53</td>
</tr>
<tr>
<td>SNAPPII score &gt; 20, n(%)</td>
<td>1,086 (79.3)</td>
<td>3,074 (80.6)</td>
<td>184 (86.8)</td>
<td>470 (86.1)</td>
<td>0.29</td>
<td>&lt; 0.01</td>
<td>&lt; 0.01</td>
</tr>
</tbody>
</table>

¹ Chi-square test for categorical variables and Wilcoxon Rank Sum test for continuous variables.

² Any resuscitation defined as mask continuous positive airway pressure or positive pressure ventilation, endotracheal tube intubation and ventilation, chest compressions, or epinephrine.

³ CPAP, continuous positive airway pressure; ETT, endotracheal tube; FiO₂, fraction of inspired oxygen; FN, fetal neuroprotection; IQR, inter-quartile range; IV, intravenous; MgSO₄, magnesium sulphate; SNAPPII, score for neonatal acute physiology II; IU, indication unknown
**Supplementary Table 3**: Univariate and multivariable outcomes of infants exposed to magnesium sulfate (any indication) compared with unexposed infants.

<table>
<thead>
<tr>
<th></th>
<th>MgSO&lt;sub&gt;4&lt;/sub&gt; for any indication&lt;sup&gt;†&lt;/sup&gt; (n = 2,147)</th>
<th>No MgSO&lt;sub&gt;4&lt;/sub&gt; (n = 3,868)</th>
<th>p-value</th>
<th>Unadjusted OR (95% CI)*</th>
<th>Adjusted OR (95% CI) *†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intensive resuscitation††, n (%)</td>
<td>840 (39.4)</td>
<td>1,702 (44.6)</td>
<td>&lt; 0.01</td>
<td>0.81 (0.73, 0.90)</td>
<td>0.87 (0.69, 1.13)</td>
</tr>
<tr>
<td>Death, n (%)</td>
<td>140 (6.5)</td>
<td>367 (9.5)</td>
<td>&lt; 0.01</td>
<td>0.67 (0.54, 0.82)</td>
<td>0.64 (0.46, 0.89)</td>
</tr>
<tr>
<td>Bronchopulmonary dysplasia, n (%)</td>
<td>418 (20.8)</td>
<td>703 (20.0)</td>
<td>0.44</td>
<td>1.05 (0.92, 1.21)</td>
<td>1.11 (0.94, 1.30)</td>
</tr>
<tr>
<td>NEC stage &gt;= 2, n (%)</td>
<td>109 (5.1)</td>
<td>197 (5.1)</td>
<td>0.99</td>
<td>0.99 (0.79, 1.27)</td>
<td>0.89 (0.68, 1.17)</td>
</tr>
<tr>
<td>Grade 3 or 4 IVH or PVL, n (%)</td>
<td>246 (12.5)</td>
<td>493 (14.3)</td>
<td>0.06</td>
<td>0.86 (0.73, 1.01)</td>
<td>1.02 (0.76, 1.36)</td>
</tr>
<tr>
<td>ROP stage &gt;= 3, n (%)</td>
<td>99 (8.8)</td>
<td>158 (8.9)</td>
<td>0.94</td>
<td>0.99 (0.76, 1.29)</td>
<td>0.86 (0.59, 1.25)</td>
</tr>
<tr>
<td>Sepsis, n (%)</td>
<td>359 (16.7)</td>
<td>587 (15.2)</td>
<td>0.11</td>
<td>1.12 (0.97, 1.30)</td>
<td>1.02 (0.87, 1.20)</td>
</tr>
<tr>
<td>Composite outcome&lt;sup&gt;§&lt;/sup&gt;, n (%)</td>
<td>729 (33.9)</td>
<td>1,378 (35.6)</td>
<td>0.19</td>
<td>0.93 (0.83, 1.04)</td>
<td>1.03 (0.85, 1.24)</td>
</tr>
</tbody>
</table>

* Unadjusted and adjusted OR determined for MgSO<sub>4</sub> vs. No-MgSO<sub>4</sub>

† Adjusted for GA, sex, small for GA, outborn status, chorioamnionitis, mode of delivery, maternal hypertension, antenatal corticosteroid use and multiple gestation using multiple logistic regression models with GEE approach to account for the correlated data within each site (or site effects).

†† Intensive resuscitation defined as need for intubation and ventilation or chest compressions or epinephrine administration in the delivery room.

§ Composite outcome defined as mortality or any major neonatal morbidity
† Including infants exposed to MgSO₄ for fetal neuroprotection, pre-eclampsia, tocolysis or for an unknown indication

IVH, intraventricular haemorrhage; MgSO₄, magnesium sulphate; NEC, necrotizing enterocolitis; PVL, periventricular leukomalacia; ROP, retinopathy of prematurity